Reshma L. Mahtani DO
Chief of Breast Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FloridaDr. Reshma L. Mahtani is a medical oncologist practicing in South Florida. She serves as Chief of Breast Medical Oncology at the Miami Cancer Institute, Baptist Health South Florida (a Memorial Sloane Kettering affiliate). She specializes in the treatment of breast cancer.
Prior to assuming her role at the Miami Cancer Institute, Dr. Mahtani was an Associate Professor of Medicine and Co-Leader of the Breast Cancer Program at Sylvester Comprehensive Cancer Center, University of Miami, where she oversaw the clinical trial program across the network. She is an active clinical researcher, and her research focuses on novel therapies for the treatment of breast cancer. She has made significant scientific and clinical practice contributions with numerous first-author publications in peer-reviewed journals.
She has served on the ASCO Quality Oncology Practice Initiative (QOPI) Steering Committee and as a member of the editorial board of The Breast Journal. She has been Program Director for several officially licensed Best of ASCO programs and is the Director of the ASCO Highlights series.
After completing her Master of Science degree in neuroscience at the University of Connecticut, Dr. Mahtani went on to the University of New England College of Osteopathic Medicine, where she received her medical degree. She completed internship at Greenwich Hospital, a Yale-affiliate, in Greenwich, Connecticut, and undertook residency training at St. Vincent’s Catholic Medical Center in New York, where she also completed her fellowship.
Disclosures
- Consultant/advisory role: Agendia; Amgen; AstraZeneca; Daiichi; Eisai; Gilead; Hologic; Lilly; Merck; Novartis; Pfizer; Puma; Sanofi; Sermonix; Stemline; Seagen
- Contracted research: Gilead
Recent Contributions to PracticeUpdate:
- Selective Estrogen Receptor Degrader Elacestrant in ER-Positive, HER2-Negative Advanced Breast Cancer
- Selecting Chemotherapy for Metastatic Breast Cancer in Clinical Practice
- Leuprorelin Combined With Letrozole ± Everolimus in Ovarian-Suppressed Premenopausal Women With HR+ HER2− Metastatic Breast Cancer
- Palbociclib in Combination With Endocrine Therapy vs Capecitabine in HR-Positive, HER2-Negative, Aromatase Inhibitor–Resistant Metastatic Breast Cancer
- Predictive Value of Circulating Tumor DNA After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
- Secondary Endpoints From a Trial of Pembrolizumab Plus Chemotherapy for Metastatic Triple-Negative Breast Cancer
- Updated Results From a Trial of Trastuzumab Deruxtecan for HER2-Positive Breast Cancer
- Alpelisib Plus Fulvestrant for PIK3CA-Mutated, HR-Positive, HER2-Negative Advanced Breast Cancer
- 2020 Top Stories in Metastatic Breast Cancer: Progress in Targeting a Sanctuary Site: Brain Mets in MBC
- Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination–Related Genes